Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

计划入组 554 人 · 首次发布于 2021 年 5 月 14 日

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

计划入组 588 人 · 首次发布于 2024 年 9 月 3 日

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

计划入组 428 人 · 首次发布于 2023 年 11 月 30 日

TVI Lung 1

ARO-ENaC

XAGE-1 derived peptide vaccine (Kawasaki Medical School)

NHI-1

United States

Lung Therapeutics, Inc.

United States

Sec Lung, LLC

United States

Landmark NSCLC Studies of 2024: LAURA, EMPOWER-Lung 1, and Beamion LUNG-1 Trials Show Promise

Zongertinib Shows Promise in HER2-Mutated NSCLC: Boehringer Ingelheim Reports Positive Phase Ib Results

Zongertinib Shows Promise in HER2-Mutated NSCLC, Phase 3 Trial Underway